HOME >> MEDICINE >> NEWS
ACTOS (pioglitazone HCl) significantly improved components of diabetic dyslipidemia

Results from the first head-to-head study between ACTOS and Avandia (rosiglitazone maleate) published in Diabetes Care

Lincolnshire, IL, June 29, 2005 A new study published in today's issue of Diabetes Care demonstrated that ACTOS improved components of diabetic dyslipidemia to a significantly greater extent than Avandia. Specifically, the results indicated that treatment with ACTOS lowered triglycerides (a type of lipid, or fat, found in food and the body), increased HDL-C ("good" cholesterol), and improved LDL-C ("bad" cholesterol) particle concentration and particle size. These differences were independent of blood glucose control and occurred without the use of a traditional lipid-lowering statin medication.

Diabetic dyslipidemia is a condition commonly found in people with type 2 diabetes and is an important risk factor for cardiovascular disease, the leading cause of death for people with type 2 diabetes. Diabetic dyslipidemia is characterized by increased triglycerides and decreased HDL-C. People with diabetic dyslipidemia also tend to have normal levels of LDL-C, but smaller, denser LDL-C particles that are likely to contribute to cholesterol build-up in arteries.

"This study provides important insight into the relative impact of each drug on important cardiovascular risk markers," noted principal investigator Ronald B. Goldberg, M.D., professor of Medicine and Associate Director of the Diabetes Research Institute at the University of Miami Miller School of Medicine. "The results demonstrate a clear difference between ACTOS and Avandia on their effects on diabetic dyslipidemia, with ACTOS lowering triglycerides and raising HDL-C to a greater extent than Avandia."

Study Design

This 24-week prospective, randomized, multicenter, double-blind clinical trial enrolled 802 people with type 2 diabetes (treated with diet alone or oral monotherapy) and dyslipidemia (not treated with any lipid-
'"/>

Contact: Amy Losak
646-935-3917
Ketchum
29-Jun-2005


Page: 1 2 3

Related medicine news :

1. ACTOS (pioglitazone HCl) demonstrates significant improvements in cardiovascular outcomes
2. ACTOS reduces stroke by almost 50 percent
3. ACTOS (pioglitazone HCl) to be studied in new trial
4. New data shows ACTOS reduced heart attacks by 28 percent in people with type 2 diabetes
5. ACTOplus met (pioglitazone HCl and metformin HCl)
6. Trial stops after stroke and mortality significantly reduced by blood
7. Investigational nonstimulant Guanfacine XR significantly improved child, adolescent ADHD symptoms
8. Full-term, low-birth-weight babies at significantly greater risk for early respiratory symptoms
9. Once-yearly treatment significantly reduces bone fractures in women with postmenopausal osteoporosis
10. New study: Pine bark significantly reduces endometriosis
11. Regular acupressure can significantly reduce agitated behavior in dementia

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... September 22, 2017 , ... Ecocor , ... Richard Pedranti Architect (RPA), a full-service architecture firm focusing on sustainable design, ... Line of Model Homes . Independently, Ecocor and RPA have extensive experience with ...
(Date:9/22/2017)... ... , ... Pullano Law Offices, a Chicago personal injury law firm, is pleased ... serve as President of the North Suburban Bar Association for 2017-2018. Mr. Pullano was ... the NSBA at the North Shore Country Club in Glenview, IL, on September 13, ...
(Date:9/22/2017)... Francisco, CA (PRWEB) , ... September 22, 2017 ... ... way to help you brush more effectively even on the go. Their electric ... like gingivitis and gum inflammation, with UV sanitizing technology. Combining leading edge Enke ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... Lyme and other tick-borne diseases through research, education and awareness, today announced the ... A noted immunologist and microbiologist, Dr. Sellati has more than 20 years of ...
(Date:9/21/2017)... ... September 21, 2017 , ... The ... Behavioral Health Services for professionals in the addiction treatment industry entitled: Special ... , Insurance companies and state and federal governments are increasingly scrutinizing the ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/7/2017)... Sept. 7, 2017  For nearly two decades, New Life Agency has ... Reproduction Insurance industry. Today, New Life Agency announces a powerful three-way partnership ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/6/2017)... -- Robert G. Szewc, M.D., is recognized by Continental Who,s ... his contributions to the Medical field.      ... practice of Kidney and Hypertension Specialists, which specializes in ... He has worked in this position since 2002, and ... as expertise in kidneys, hypertension, chronic disease and anemia, ...
Breaking Medicine Technology:
Cached News: